Since Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) and Arcturus Therapeutics Ltd. (NASDAQ:ARCT) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation of both companies.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Navidea Biopharmaceuticals Inc	1.17M	30.02	16.16M	-0.12	0.00
Arcturus Therapeutics Ltd.	15.75M	5.45	21.79M	-4.19	0.00

Demonstrates Navidea Biopharmaceuticals Inc and Arcturus Therapeutics Ltd. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 shows us the return on assets, return on equity and net margins of both companies.

	Net Margins	Return on Equity	Return on Assets
Navidea Biopharmaceuticals Inc	-1,381.20%	-355.9%	-119.6%
Arcturus Therapeutics Ltd.	-138.35%	0%	0%

Volatility & Risk

Navidea Biopharmaceuticals Inc’s current beta is 0.82 and it happens to be 18.00% less volatile than Standard & Poor’s 500. Competitively, Arcturus Therapeutics Ltd. is 109.00% more volatile than Standard & Poor’s 500, because of the 2.09 beta.

Analyst Recommendations

In next table is shown Navidea Biopharmaceuticals Inc and Arcturus Therapeutics Ltd.’s ratings and recommendations.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Navidea Biopharmaceuticals Inc	0	0	0	0.00
Arcturus Therapeutics Ltd.	0	0	1	3.00

Meanwhile, Arcturus Therapeutics Ltd.’s consensus target price is $15, while its potential upside is 87.97%.

Insider & Institutional Ownership

Roughly 5.5% of Navidea Biopharmaceuticals Inc shares are owned by institutional investors while 14.6% of Arcturus Therapeutics Ltd. are owned by institutional investors. 12.3% are Navidea Biopharmaceuticals Inc’s share owned by insiders. Competitively, insiders own roughly 23.9% of Arcturus Therapeutics Ltd.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Navidea Biopharmaceuticals Inc	1.15%	1.95%	-14.36%	-4.02%	-53.27%	62.68%
Arcturus Therapeutics Ltd.	3.88%	1.8%	-16.69%	-36.69%	-7.96%	12.36%

For the past year Navidea Biopharmaceuticals Inc was more bullish than Arcturus Therapeutics Ltd.

Summary

On 7 of the 11 factors Arcturus Therapeutics Ltd. beats Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It is also developing NAV5001, an Iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinsons disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs and therapeutics. Navidea Biopharmaceuticals, Inc. has research and development agreements with University of California, San Diego. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

Arcturus Therapeutics Ltd. operates as an RNA medicines company. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 120 patents and patent applications issued in the United States, Europe, Japan, China, and other countries. Its proprietary UNA technology is used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. The company develops novel RNA therapeutics through its partnerships with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., and Cystic Fibrosis Foundation Therapeutics Inc. Arcturus Therapeutics Ltd. has a strategic collaboration with CureVac AG to jointly discover, develop, and commercialize novel messenger RNA therapeutics. The company was founded in 2013 and is headquartered in San Diego, California.